According to the research report titled ‘Global Dry Eye Disease (DED) Market - Analysis By Disease (Aqueous, Evaporative, Others), Treatment, End User, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid -19 Impact, Competition and Forecast (2021-2026)’, available with MarketStudyReport, global dry eye disease (DED) market was worth USD 5378.59 million in 2020 and is anticipated to showcase lucrative growth trends between 2021 and 2026.
 

Increasing life expectancy, rising elderly population, growing pool of working population with longer screen timings, and rapid lifestyle changes are the major factors driving global dry eye disease market growth.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/3542234/
 

Based on disease, the industry is segmented into aqueous, and evaporative including others. As cited in the report, evaporative dry eye disease market segment is expected to hold a substantial share in the forthcoming years, owing to the high prevalence of the disorder with associated meibomian gland dysfunction.
 

Considering the end user spectrum, the marketplace is fragmented into home health care, hospitals, and clinics. Among these, hospitals segment, followed by clinics, is anticipated to acquire a considerable market share by the year 2026, primarily due to increasing number of people suffering from eye disorders, focus towards creating awareness, and mounting investments to expand the manufacturing capacity.
 

Speaking of treatment type, worldwide dry eye disease market is categorized into eye drops, and anti-inflammatory drugs among others. Moving on to distribution channel, the business space is bifurcated into retailers, hospital pharmacies, online, and others.
 

As per the regional framework, North America, followed by Europe and Asia Pacific, is expected to spur the industry growth graph over the analysis timeframe. This can be credited to the presence of prominent manufactures boosting their production capacities and rising number of people suffering from dry eye diseases due to longer screen times in the region.
 

Prominent players in worldwide dry eye disease industry are Novaliq GmbH, Horus Pharma, Sentiss Pharma Pvt. Ltd., VISUfarma B.V., Novartis International AG, Allergan plc, Alcon, Santen Pharmaceutical Co. Ltd., Bausch Health Companies Inc., and Johnson & Johnson.